By Fineline Cube 
Goodrx Holdings Inc (NASDAQ: GDRX), the leading platform for medication savings in the U.S., has partnered with Novo Nordisk (NYSE: NVO) to offer all strengths of semaglutide (Ozempic and Wegovy) pens to eligible self-paying patients at $499 per month through GoodRx.
Price Reduction and Impact
This collaboration significantly lowers the price of two of the most in-demand GLP-1 medications nationwide, expanding access for those lacking adequate insurance coverage. Today also marks the first time Ozempic has been made available to patients at this self-pay price.
Conclusion
The partnership between GoodRx and Novo Nordisk highlights the growing trend of collaborations aimed at making high-demand medications more affordable for self-paying patients, setting a precedent for future pricing strategies in the pharmaceutical industry.-Fineline Info & Tech